Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer

Lancet Gastroenterol Hepatol. 2023 Mar;8(3):211. doi: 10.1016/S2468-1253(22)00402-2.

Authors

Ruveyda Ayasun¹, Ilyas Sahin²

Affiliations

¹ Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
² Division of Hematology and Oncology, Department of Medicine, University of Florida Health Cancer Center, Gainesville, FL 32608, USA. Electronic address: i.sahin@ufl.edu.

PMID: 36773612
DOI: 10.1016/S2468-1253(22)00402-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents, Immunological* / therapeutic use
Biliary Tract Neoplasms* / drug therapy
Humans
Receptor, ErbB-2
Trastuzumab / therapeutic use

Substances

Trastuzumab
Receptor, ErbB-2
Antineoplastic Agents, Immunological